Bellevue Group’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.06M | Buy |
421,501
+392,571
| +1,357% | +$6.58M | 0.16% | 73 |
|
|
2025
Q1 | $445K | Sell |
28,930
-31,668
| -52% | -$487K | 0.01% | 120 |
|
|
2024
Q4 | $1.34M | Sell |
60,598
-10,223
| -14% | -$225K | 0.03% | 112 |
|
|
2024
Q3 | $1.28M | Sell |
70,821
-83,949
| -54% | -$1.51M | 0.02% | 113 |
|
|
2024
Q2 | $2.52M | Buy |
154,770
+12,557
| +9% | +$204K | 0.04% | 109 |
|
|
2024
Q1 | $2.01M | Buy |
+142,213
| New | +$2.01M | 0.03% | 108 |
|
|
2020
Q2 | – | Sell |
-303,000
| Closed | -$2.72M | – | 224 |
|
|
2020
Q1 | $2.72M | Buy |
303,000
+37,000
| +14% | +$332K | 0.05% | 124 |
|
|
2019
Q4 | $2.61M | Buy |
266,000
+116,000
| +77% | +$1.14M | 0.04% | 125 |
|
|
2019
Q3 | $1.03M | Buy |
+150,000
| New | +$1.03M | 0.02% | 143 |
|
|
2019
Q1 | – | Sell |
-60,000
| Closed | -$925K | – | 147 |
|
|
2018
Q4 | $925K | Hold |
60,000
| – | – | 0.06% | 118 |
|
|
2018
Q3 | $1.29M | Sell |
60,000
-30,000
| -33% | -$646K | 0.08% | 118 |
|
|
2018
Q2 | $2.19M | Hold |
90,000
| – | – | 0.19% | 85 |
|
|
2018
Q1 | $1.54M | Sell |
90,000
-581,940
| -87% | -$9.94M | 0.15% | 93 |
|
|
2017
Q4 | $12.7M | Buy |
671,940
+90,000
| +15% | +$1.71M | 1.33% | 28 |
|
|
2017
Q3 | $10.2M | Buy |
581,940
+296,611
| +104% | +$5.22M | 1.07% | 33 |
|
|
2017
Q2 | $9.48M | Sell |
285,329
-80,843
| -22% | -$2.69M | 1.12% | 35 |
|
|
2017
Q1 | $11.8M | Buy |
366,172
+131,182
| +56% | +$4.21M | 1.57% | 23 |
|
|
2016
Q4 | $8.52M | Buy |
234,990
+47,800
| +26% | +$1.73M | 1.74% | 21 |
|
|
2016
Q3 | $8.61M | Sell |
187,190
-42,000
| -18% | -$1.93M | 1.56% | 23 |
|
|
2016
Q2 | $11.5M | Buy |
229,190
+33,900
| +17% | +$1.7M | 2.17% | 12 |
|
|
2016
Q1 | $10.5M | Buy |
+195,290
| New | +$10.5M | 1.9% | 13 |
|